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The purpose of this review is to try to take 
a practical approach toward the management of pa-
tients with renal calculous disease. This will be a 
personal approach; I will, however, try to avoid 
injecting my prejudices and research interests. I 
want to show that proper management can be 
achieved even in the most unsophisticated environ-
ment. 
Clinical Evaluation. It is often true that the 
first evaluation is the most important in giving a 
clue to underlying cause. Therefore, every effort 
must be made to avoid failure and thus discourage 
both clinician and patient. Patients with renal stones 
generally seek help when they are experiencing 
symptoms which may be due to partial obstruction 
with loss of appetite and perhaps partial dehydra-
tion. This is not the time to investigate one's pa-
tient as the underlying metabolic disorder may be 
completely obscured. Thus, delay until the patient 
has resumed his normal state is important. 
I do not believe that it is worthwhile in this 
area to submit a patient to an evaluation who has 
passed and/or made a single stone. We live in a 
stone belt. In this area, 80% of the patients who 
have made only one stone will not make another. 
In the remaining percentage of patients who have 
made one stone, there is nearly an 80% chance that 
they will make another within a year. As yet we 
have no test available to us that will allow us to 
distinguish the true stone former. 
A careful history must probe for previm.is epi-
sodes and associated conditions such as urinary in-
fections, excessive dehydration, diarrhea, fractures 
with prolonged immobilization, high alkali, Vitamin 
D or milk intake. Certain drugs, for example 
Diamox® and steroids, are associated with stone 
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formation. A family history of calculi is often present 
and may be so prominent, as in cystinuria or oxaluria, 
that the patient already knows the diagnosis. 
A careful urinalysis with recording of the pH, 
crystal content, and presence of bacteria is still the 
best single test in the management of these patients. 
The following · laboratory evaluations are im-
portant and can be done while in the hospital or as 
an out-patient: 
1) Urine for culture and sensitivity. 
2) Urine for cyanide-nitroprusside test (screen-
ing for cystine). 
3) Teach the patient to test the pH of every 
voided specimen of urine with nitrazine 
paper (Lilly Company). 
4) Three determinations of serum calcium, 
phosphorus, uric acid, and creatinine and 
additional routine determinations of total 
protein, albumin, alkaline phosphatase, and 
electrolytes. · 
5) Three · 24-hour urines for calcium, phos-
phorus, magnesium, uric acid, and cre-
atinine. 
6) Analysis of stones should include x-ray 
diffraction or crystallographic analysis which 
is readily available. This is very important 
because, at this time, medical management 
is directed toward the crystalline com-
ponents. 
7) Plain film of the abdomen with an intra-
venous pyelogram. The roentgenographic 
appearance of calculi with particular at-
tention to the position in the parenchyma 
or collecting system and also evidence of 
layering of calcium over a possibly radio-
lucent nidus are most important in arriving 
at the diagnosis for a specific cause of a 
stone and thus planning the therapy. It 
goes without saying that it is necessary to 
exclude all forms of obstruction, and at-
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tention should be paid to whether there is 
parenchymal calcification which can take 
various forms. A peppering of small calculi 
outlining the renal papilla often suggests 
renal tubular acidosis; however, if this is 
confined to only one papilla then one would 
think more of a medullary sponge kidney. 
If there is evidence of infection of the 
urinary tract, then I believe that a voiding 
cystourethrogram should always be carried 
out to detect the presence of vesicoureteral 
reflux. 
Calculi. 
Uric Acid Calculi. In this area, uric acid 
calculi make up 15% of all calculi seen. They are 
the only truly radiolucent stones and are not neces-
sarily associated with hyperuricemia and hyper-
uricosuria. They are most often associated with 
excretion of unusually acid urine and repeated bouts 
of dehydration. One may see these types of stones 
in patients with chronic diarrhea. Certain cytotoxic 
drugs, particularly those used in the treatment of 
lymphomas and leukemia, the thiazides, salicylates, 
and steroids will cause uricosuria, and in the pres-
ence of low urinary pH, uric acid stones can form. 
Patients will respond very rapidly to a program 
of high urinary output and alkalization. The patient 
must continually check his urine, particularly the 
morning specimen, and adjust the dosage of bi-
carbonate so that the pH is above 6.0. 
In some patients it may be necessary to add 
allopurinol to the regimen, and the dosage will vary 
from 100-800 mg daily. This potent enzyme in-
hibitor will prevent further uric acid calculi for-
mation, but there is the theoretical possibility of 
xanthine stone formation so alkalization must be 
continued to prevent this possibility. 
At present, it is possible to completely prevent 
uric acid calculi. Surgery should play a minimal 
part in the management of these patients even when 
stones are present in the urinary tract. It has long 
been known that high output of alkaline urine will 
sometimes dissolve these stones. The introduction 
of allopurinol to the armamentarium has provided 
some dramatic cures. I have five patients in whom 
uric acid staghorns have completely dissappeared 
after an average of six months. 
Cystine Calculi. The diagnosis of this familial 
disease will usually follow from the routine testing 
noted above and the finding of hexagonal crystals 
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in acid urine. One should stress again that these 
stones are radio-opaque because of their 27% con-
tent of sulphur and that they have a typical ground 
glass appearance. 
At the Medical College of Virginia, we have 
an unusually high incidence of cystine stones be-
cause of the presence of this inherited metabolic 
disease in the Chickahominy Indians. Usually, the 
incidence is only 0.5-1 % of all stones. 
Therapy is directed toward maintaining the 
urinary volume in excess of 2,500 ml per day, in-
cluding an intake of at least 500 ml of fluids in the 
mid-sleep hours. The urine is, maintained alkaline, 
and the patient is instructed to check his urine and 
adjust the dosage of his alkalizing medication in 
order to keep the pH of the urine above 6.5. If the 
patient follows such a regimen conscientiously, the 
solubility of cystine in urine will increase and further 
stone formation may not occur. This can readily be 
checked by routine urinalysis. Patients who are un-
successful in such therapy may require the addition 
of n-penicillamine to the treatment program. This 
drug is given in dosages of 1-4 g per day guided 
by the screening tests for cystine (nitroprusside 
tests). 
n-Penicillamine is not completely without its 
complications; a rash may occur but can be abated 
by stopping the medication for two weeks and then 
resuming it by gradually increasing it from 250 mg 
per day to the required daily dose. Nephrotic syn-
drome has occurred and requires cessation of the 
therapy along with prolonged medical observation. 
There is an increasing number of reports of patients 
losing their sense of taste while on this drug. 
Reappearance of the stones or failure of the 
stones to dissolve might imply failure of therapy. 
On several occasions, however, we have found that 
this was due to the production of stones of other 
chemical makeup; therefore, these patients must be 
very carefully followed and watched in case such an 
event occurs. 
It is extremely important when treating these 
patients with penicillamine to keep the dose as low 
as possible, that is, to keep the urinary cystine level 
below 250 mg per day by the minimum dose of 
o-penicillamine possible. It is conceivable, and we 
have seen it here on two occasions, that prolonged 
high doses of penicillamine will interfere with col-
lagen maturation and thus give rise to bruising and 
striae formation; great care must be exercised in the 
management of these patients. 
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Calcium Calculi. The stones that contain cal-
cium are found in a wide spectrum of conditions 
that can be broken down into individual management 
problems once the proper diagnosis has been made. 
The principal breakdown is into those patients with 
or without infection. One should not lose sight of 
the fact that many so-called infectious stones may 
have had as a nucleus an uninfected stone so one 
should adjust the therapeutic attack accordingly. 
Triple Phosphate Calculi. Stones associated 
with infection imply the presence of stones containing 
varying amounts of calcium magnesium ammonium 
phosphate. Their roentgen appearance is variable as 
they may have a high content of so-called matrix. 
Therapy is directed toward eliminating the infection. 
It is essential to correct obstruction, diabetes and 
hyperparathyroidism, and to remove all foreign bod-
ies; otherwise, any therapy directed toward the infec-
tion will be doomed to failure. 
Appropriate antibiotic therapy must be intensive 
and often prolonged until the urine is sterile and 
stays that way. Acidification of the urine is certainly 
very helpful. A regimen using methenamine and 
ascorbic acid is helpful. We have found that in some 
patients methylene blue will lower the urinary pH, 
and it seems to prevent organization of the matrix 
and prevents it from binding the calcium ions. 
Oral use of magnesium or phosphates is con-
traindicated. If one can lower the urinary phosphorus 
by use of a low phosphorus-containing diet and 
Basaljel®, then success has been achieved. It is often 
extremely difficult to insure that patients remain on 
this regimen, however, and I no longer use it except 
with very compulsive patients. 
I believe it can rarely be said that a stone is 
purely secondary to infection. 
Calcium Oxalate and Calcium Phosphate. Prior 
to discussion of the management of these common 
stones, a few general observations should be made. 
Pure calcium phosphate stones are most commonly 
found in association with metabolic diseases; for 
example, hyperparathyroidism, renal tubular acidosis, 
immobilization syndrome, and stones associated with 
the hypercalcemia of malignant disease and sar-
coidosis; a more intensive investigation by a meta-
bolic unit is indicated. Many patients will alternate 
calcium oxalate and phosphate stones, presumably 
due to the variation in urinary pH, as calcium phos-
phate precipitates at high urinary pH. Hyperoxaluria 
should be suspected in children or young patients 
with recurrent stone formation. 
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Calcium oxalate and/ or phosphate calculi repre-
sent a disease complex which has many factors as-
sociated with it, and therefore, it seems that one 
should direct attention and therapy toward the most 
prominent biochemical abnormality that the pre-
liminary investigation turns up; always remember 
that continuous monitoring and flexibility are es-
sential. 
Hypercalciuria. There is still considerable 
controversy as to the best therapy for this common 
problem. The following therapies are recommended: 
Thiazides. If given in a dosage of 500 mg twice 
daily, they will reduce the urinary calcium and ele-
vate the magnesium. There are certain side effects, 
however, which may be potentially harmful. Meta-
bolic acidosis and potassium deficiency have been 
reported. Citrate excretion is practically abolished 
and hyperuricemia may occur. Rarely, this will cause 
hypercalcemia unmasking that group of people who 
exhibit normocalcemic hyperparathyroidism. All of 
these patients must be warned to keep their sodium 
intake low, or the effect of the thiazides will be nulli-
fied. It is questionable whether this form of therapy 
should be combined with the phosphate type as there 
exists the potential of exacerbating the renal damage 
that can occur from phosphate ingestion. 
Neutral Orthophosphate. In 1958 and 1959, 
Drs. Howard and Thomas made a crucial observa-
tion concerning "evil urine" and its ability to calcify 
rachitic rat cartilage while good urine would not 
do this. This led to the discovery that neutral ortho-
phosphate taken orally will consistently lower urinary 
calcium and convert evil to good urine. Subsequent 
work by others in the field has confirmed that a 
dosage of 1.3-1.5 g per day is sufficient to stop stone 
formation. Unfortunately, this dosage is sometimes 
limited by the diarrhea which may occur. 
Uricosuria. There is a group of patients whose 
only detectable metabolic abnormality was a relative 
uricemia and uricosuria. Interestingly, these patients 
often belong to the so-called "young executive stone 
former." It has been possible to control their oxalate 
stone formation with a low dosage of allopurinol 
(50 mg) and alkalization. 
Calcium/Magnesium Ratio. There is a group 
of stone formers who have a ratio of these ions to 
each other greater than three and who appear to 
benefit from magnesium oxide therapy usually ad-
ministered as Milk of Magnesia® tablets. I should 
stress that some workers have not been able to 
demonstrate these differences so that if one uses 
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this therapy, very careful monitoring and study is 
essential. 
Lack of Detectable Abnormality. There is a 
group of people in whom there is no detectable ab-
normality on the biochemical survey. A variety of 
therapeutic approaches is currently under study. 
Dr. Prien is presently conducting a study on 
the effect of magnesium oxide (300 mg per day) 
and pyridoxine (10 mg per day) in the.management 
of recurrent stone formers. He will provide the 
protocol and therapy in return for follow-up results. 
Studies on methylene blue by Boyce and by 
Smith have been reported previously. At this time, 
methylene blue ( 65 mg three times a day) would 
seem to be effective in preventing the formation of 
stones in uninfected calcium oxalate stone formers. 
I admit that it may also be helpful in "urine watch-
ers" in that they will tend to keep up an adequate 
fluid intake. 
Discredited Therapy. Aspirin, hyaluronidases, 
and cranberry juice have fallen into disrepute as 
forms of therapy. 
General Measures. As has been indicated, each 
patient will require individualized therapy. It is ex-
tremely important to be prepared to evaluate patients 
continually as to their response to a particular 
therapy and, if necessary, to shift to another. 
Dietary therapy is not emphasized; however, all 
patients are instructed in a simple low calcium diet. 
There are a few people who can remain on diets 
and successfully reduce the urinary calcium levels. 
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All patients are taught to measure their urine vol-
ume and to aim to maintain an output above 100 
ml in one hour. It is probably wise to advise patients 
to avoid excessive consumption of soft drinks, since 
a carbohydrate load has been shown to induce hyper-
calciuria of frightening proportions. I believe the 
intelligent participation by a patient in his medical 
management is probably the single most important 
facet in the management of recurrent urinary calculi. 
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